Atherosclerosis, 88 (1991) 255–257
© 1991 Elsevier Scientific Publishers Ireland, Ltd. 0021-9150/91/$03.50

Author Index (Vol. 88)

Aikawa, T., see Kurosaka, D. (88) 15
Andersson, A., Isaksson, A., Brattström, L., Israelsson, B. and Hultberg, B.
Influence of hydrolysis on plasma homocysteine determination in healthy subjects and patients with myocardial infarction (88) 143
Ausman, L.M., see Nicolosi, R.J. (88) 133
Aviram, M., Cogan, U. and Mokady, S.
Excessive dietary tryptophan enhances plasma lipid peroxidation in rats (88) 29
Aviram, M., see Maor, I. (88) 163

Bagge, U., see Wysocki, M. (88) 21
Baraga, J.J., Rava, R.P., Fitzmaurice, M., Tong, L.L., Taroni, P., Kittrell, C. and Feld, M.S.
Characterization of the fluorescent morphological structures in human arterial wall using ultraviolet-excited microspectrofluorimetry (88) 1
Barboriak, J.J., see Hojnacki, J.L. (88) 49
Barrow, D.V., see Gross, P.L. (88) 76
Braide, M., see Wysocki, M. (88) 21
Brattström, L., see Andersson, A. (88) 143
Bright, C.P., see Parrott, D.P. (88) 213
Brook, G.J., see Maor, I. (88) 163

Chin, H.P., see Gray, D.S. (88) 93
Cluette-Brown, J.E., see Hojnacki, J.L. (88) 49
Cogan, U., see Aviram, M. (88) 29

Danse, L.H.J.C., see Joles, J.A. (88) 35
Deschenes, R.N., see Hojnacki, J.L. (88) 49

Erkelens, D.W., see Joles, J.A. (88) 35

Feld, M.S., see Baraga, J.J. (88) 1
Fidge, N., see Sviridov, D. (88) 235
Fischer, J., see Rauh, G. (88) 219
Fitzmaurice, M., see Baraga, J.J. (88) 1
Franceschini, G., Maderna, P. and Sirtori, C.R.
Reverse cholesterol transport: physiology and pharmacology (88) 99
Fukuzumi, H., see Horie, M. (88) 183

Geelhoed-Mieras, M.M., see Joles, J.A. (88) 35
Gianfranceschi, G., see Sirtori, M. (88) 249
Goto, Y., see Homma, Y. (88) 175
Gray, D.S., Sharma, R.C., Chin, H.P. and Kramsch, D.M.
Body fat distribution affects responses to high fat cholesterol containing diet in male cynomolgus monkeys (88) 93
Gries, A., see Malle, E. (88) 193
Gross, P.L., Rand, M.L., Barrow, D.V. and Packham, M.A.
Platelet hypersensitivity in cholesterol-fed rabbits: enhancement of thromboxane A_2-dependent and thrombin-induced, thromboxane A_2-independent platelet responses (88) 76

Hankowitz, J., see Schmitz, G. (88) 109
Hegsted, D.M., see Nicolosi, R.J. (88) 133
Hermetter, A., see Malle, E. (88) 193
Hojnacki, J.L., Deschenes, R.N., Cluette-Brown, J.E., Mulligan, J.J., Osmolski, T.V., Rencricca, N.J. and Barboriak, J.J.
Effect of drinking pattern on plasma lipoproteins and body weight (88) 49
Homma, Y., Moriguchi, E.H., Sakane, H., Ozawa, H., Nakamura, H. and Goto, Y.
Effects of probucol on plasma lipoprotein subfractions and activities of lipoprotein lipase and hepatic triglyceride lipase (88) 175
Horie, M., Sawasaki, Y., Fukuzumi, H., Watanabe, K., Iizuka, Y., Tsuchiya, Y. and Kamei, T.
Hypolipidemic effects of NB-598 in dogs (88) 183
Horinuki, R., see Yoshino, G. (88) 69
Hultberg, B., see Andersson, A. (88) 143

Iizuka, Y., see Horie, M. (88) 183
Isaksson, A., see Andersson, A. (88) 143
Israelsson, B., see Andersson, A. (88) 143

Joles, J.A., Willekes-Koolschijn, N., Van Tol, A., Geelhoed-Mieras, M.M., Danse, L.H.J.C., Van Garderen, E., Kortlandt, W., Erkelens, D.W. and Koomans, H.A.
Hyperlipoproteinemia in one-year-old analbuminemic rats (88) 35

Kamei, T., see Horie, M. (88) 183
Kawano, M., see Morisaki, N. (88) 227
Kazumi, T., see Yoshino, G. (88) 69
Keller, C., see Rauh, G. (88) 219
Kimura, Y., see Yoshino, G. (88) 69
Kittrell, C., see Baraga, J.J. (88) 1
Koomans, H.A., see Joles, J.A. (88) 35

Kortlandt, W., see Joles, J.A. (88) 35
Koshikawa, T., see Morisaki, N. (88) 227
Kostner, G.M., see Malle, E. (88) 193
Kovacs, E.M., see Schmitz, G. (88) 109
Koyama, N., see Morisaki, N. (88) 227
Kramsch, D.M., see Gray, D.S. (88) 93
Krotkiewski, M., see Wysocki, M. (88) 21
Kurokawa, K., see Kurosaka, D. (88) 15
Kurosaka, D., Teramoto, T., Matsushima, T., Yokoyama, T., Yamada, A., Aikawa, T., Miyamoto, Y. and Kurokawa, K.
Apolipoprotein E deficiency with a depressed mRNA of normal size (88) 15

Laakso, M., see Mykkänen, L. (88) 153
Leis, H.J., see Malle, E. (88) 193
Lockey, P.M., see Parrott, D.P. (88) 213

Maderna, P., see Franceschini, G. (88) 99
Maeda, E., see Yoshino, G. (88) 69
Malle, E., Sattler, W., Prenner, E., Leis, H.J., Hermetter, A., Gries, A. and Kostner, G.M.
Effects of dietary fish oil supplementation on platelet aggregability and platelet membrane fluidity in normolipemic subjects with and without high plasma Lp(a) concentrations (88) 193
Maor, I., Brook, G.J. and Aviram, M.
Platelet secreted lipoprotein-like particle is taken up by the macrophage scavenger receptor and enhances cellular cholesterol accumulation (88) 163
Matsuba, K., see Yoshino, G. (88) 69
Matsushima, T., see Kurosaka, D. (88) 15
Matsushita, M., see Yoshino, G. (88) 69
McCully, K.S., see Olszewski, A.J. (88) 61
Michishita, I. and Thompson, G.R.
Cholesterol flux in cholesterol ester-loaded macrophages in an in vitro perfusion system (88) 203
Miyamoto, Y., see Kurosaka, D. (88) 15
Mokady, S., see Aviram, M. (88) 29
Moriguchi, E.H., see Homma, Y. (88) 175
Morisaki, N., Kawano, M., Koyama, N., Koshikawa, T., Umemiya, K., Saito, Y. and Yoshida, S.
Effects of transforming growth factor-β_1 on growth of aortic smooth muscle cells. Influences of interaction with growth factors, cell state, cell phenotype, and cell cycle (88) 227
Morita, M., see Yoshino, G. (88) 69
Mulligan, J.J., see Hojnacki, J.L. (88) 49
Mykkänen, L., Laakso, M., Penttilä, I. and Pyörälä, K.
Asymptomatic hyperglycemia and cardiovascular risk factors in the elderly (88) 153

Nagata, K., see Yoshino, G. (88) 69
Nakamura, H., see Homma, Y. (88) 175
Nicolosi, R.J., Ausman, L.M. and Hegsted, D.M.
Rice bran oil lowers serum total and low density lipoprotein cholesterol and apo B levels in nonhuman primates (88) 133
Nicolosi, R.J., see Terpstra, A.H.M. (88) 243

Olszewski, A.J. and McCully, K.S.
Homocysteine content of lipoproteins in hypercholesterolemia (88) 61
Olszewski, A.J.
Homocysteine content of plasma in ischemic heart disease, reducing the effect of pyridoxine, folate, cobalamin, choline, riboflavin and troxerutin. Correction of a calculation error (88) 97
Orlandi, A., see Spagnoli, L.G. (88) 87
Osmolski, T.V., see Hojnacki, J.L. (88) 49
Ozawa, H., see Homma, Y. (88) 175

Packham, M.A., see Gross, P.L. (88) 76
Parrott, D.P., Lockey, P.M. and Bright, C.P.
Comparison of the mitogenic activity of angiotensin II and serotonin on porcine arterial smooth muscle cells (88) 213
Pazzucconi, F., see Sirtori, M. (88) 249
Penttilä, I., see Mykkänen, L. (88) 153
Prenner, E., see Malle, E. (88) 193
Pyörälä, K., see Mykkänen, L. (88) 153

Rand, M.L., see Gross, P.L. (88) 76
Rauh, G., Schuster, H., Fischer, J., Keller, C., Wolfram, G. and Zöllner, N.
Familial defective apolipoprotein B-100: haplotype analysis of the arginine$_{(3500)}$ → glutamine mutation (88) 219
Rava, R.P., see Baraga, J.J. (88) 1
Rencricca, N.J., see Hojnacki, J.L. (88) 49
Repin, V., see Sviridov, D. (88) 235

Saito, Y., see Morisaki, N. (88) 227
Sakane, H., see Homma, Y. (88) 175
Santeusanio, G., see Spagnoli, L.G. (88) 87
Sattler, W., see Malle, E. (88) 193
Sawasaki, Y., see Horie, M. (88) 183
Schmitz, G., Hankowitz, J. and Kovacs, E.M.
Cellular processes in atherogenesis: potential targets of Ca^{2+} channel blockers (88) 109
Schuster, H., see Rauh, G. (88) 219
Sharma, R.C., see Gray, D.S. (88) 93
Sirtori, C.R., see Franceschini, G. (88) 99
Sirtori, C.R., see Sirtori, M. (88) 249
Sirtori, M., Pazzucconi, F., Gianfranceschi, G. and Sirtori, C.R.
Efficacy of cholestyramine does not vary when taken before or during meals (88) 249
Smirnov, V., see Sviridov, D. (88) 235
Spagnoli, L.G., Orlandi, A. and Santeusanio, G.
Foam cells of the rabbit atherosclerotic plaque arrested in metaphase by colchicine show a macrophage phenotype (88) 87
Stucchi, A.F., see Terpstra, A.H.M. (88) 243
Sviridov, D., Fidge, N., Repin, V. and Smirnov, V.
Effect of lovastatin on the interaction between high density lipoprotein and cultured rat adrenocortical cells (88) 235

Tani, T., see Yoshino, G. (88) 69
Taroni, P., see Baraga, J.J. (88) 1
Teramoto, T., see Kurosaka, D. (88) 15
Terpstra, A.H.M., Stucchi, A.F. and Nicolosi, R.J.
Estimation of HDL cholesteryl ester kinetic parameters in the cebus monkey, an animal species with high plasma cholesteryl ester transfer activity (88) 243
Thompson, G.R., see Michishita, I. (88) 203
Tong, L.L., see Baraga, J.J. (88) 1
Tsuchiya, Y., see Horie, M. (88) 183

Umemiya, K., see Morisaki, N. (88) 227

Van Garderen, E., see Joles, J.A. (88) 35
Van Tol, A., see Joles, J.A. (88) 35

Watanabe, K., see Horie, M. (88) 183
Willekes-Koolschijn, N., see Joles, J.A. (88) 35
Wolfram, G., see Rauh, G. (88) 219
Wysocki, M., Krotkiewski, M., Braide, M. and Bagge, U.
Hemorheological disturbances, metabolic parameters and blood pressure in different types of obesity (88) 21

Yamada, A., see Kurosaka, D. (88) 15
Yokoyama, T., see Kurosaka, D. (88) 15
Yoshida, S., see Morisaki, N. (88) 227
Yoshino, G., Matsushita, M., Maeda, E., Nagata, K., Morita, M., Matsuba, K., Tani, T., Horinuki, R., Kimura, Y. and Kazumi, T.
Effect of probucol on triglyceride turnover in streptozotocin-diabetic rats (88) 69

Zöllner, N., see Rauh, G. (88) 219

Atherosclerosis, 88 (1991) 259–260
© 1991 Elsevier Scientific Publishers Ireland, Ltd. 0021-9150/91/$03.50

Subject Index (Vol. 88)

Adrenocortical cells, (88) 235
Aged, (88) 153
Analbuminemia, (88) 35
Angiotensin II, (88) 213
Anion-exchange resins, (88) 249
Apolipoprotein, (88) 35
Apolipoprotein A-I/phosphatidylcholine complexes, (88) 203
Apolipoprotein B-100, (88) 219
Apolipoprotein E, (88) 15
Apolipoprotein E deficiency, (88) 15
Aspirin, (88) 76
Atherogenic index, (88) 61
Atherosclerosis, (88) 1; (88) 61; (88) 87; (88) 109; (88) 213; (88) 219

Bile acids, (88) 183
Binge drinking, (88) 49
Body mass index, (88) 49

Ca^{2+} channel blocker, (88) 109
Cardiovascular risk factors, (88) 21
Cell cycle, (88) 227
Cholesterol, (88) 163; (88) 183; (88) 243
Cholesterol reduction, (88) 249
Cholesteryl esters, (88) 243
Cholesteryl ester transfer activity, (88) 243
Cholesteryl ester transfer protein, (88) 99
Cholestyramine, (88) 249
Colchicine, (88) 87
Collagen, (88) 1
Coronary heart disease, (88) 153

Diabetes mellitus, non-insulin-dependent, (88) 153
Dietary cholesterol, (88) 76
Dietary tryptophan, (88) 29
Dog, (88) 183

Efflux, (88) 203
Elastin, (88) 1
Epidermal growth factor, (88) 213

Fluorescence anisotropy, (88) 193
Fluorescence microscopy, (88) 1

Genetic mutation, (88) 219

Haplotypes, (88) 219
HDL, (88) 203
HDL subfractions, (88) 99
Hemorheology, (88) 21
Hepatic triglyceride lipase, (88) 175
High density lipoprotein, (88) 133; (88) 235
HMG-CoA reductase inhibitor, (88) 235
Homocysteine, (88) 61; (88) 143
Hydrolysis, (88) 143
Hypercholesterolemia, (88) 76; (88) 133; (88) 219
Hyperglycemia, (88) 153
Hyperlipidemia, (88) 35
Hyperlipoproteinemia, (88) 175
Hypertension, (88) 153; (88) 213
Hypolipidemic drug, (88) 183

Immunohisto chemistry, (88) 87
Influx, (88) 203
Insulin, (88) 21

J774 cells, (88) 203

LDL, (88) 203; (88) 219
Lecithin:cholesterol acyltransferase, (88) 49; (88) 99
Lipid metabolism, (88) 109
Lipid peroxidation, (88) 29
Lipids, (88) 153
Lipofuscinosis, (88) 35
Lipoprotein(a), (88) 193
Lipoprotein fractions, (88) 61
Lipoprotein lipase, (88) 175
Lipoproteins, (88) 49; (88) 153; (88) 163; (88) 183; (88) 243
Lipoprotein subfraction, (88) 175
Lovastatin, (88) 235
Low density lipoprotein, (88) 133

Macrophage proliferation, (88) 87
Membrane fluidity, (88) 193
Membrane integrity, (88) 109
Metabolism, (88) 243
Microspectrofluorimetry, (88) 1
Mitogenesis, (88) 213
Mitosis, (88) 87
Monkeys, (88) 243
Monocyte, (88) 15
Monounsaturated fat, (88) 133
Myocardial infarction, (88) 143

NB-598, (88) 183
$n-3$ polyunsaturated fatty acids, (88) 193

Obesity, (88) 21; (88) 153

Phenotype, (88) 227
Plasma, (88) 143
Platelet aggregation, (88) 193
Platelet-derived growth factor, (88) 213
Platelet hypersensitivity, (88) 76
Platelets, (88) 163
Platelet thromboxane formation, (88) 76
Polyunsaturated fat, (88) 133
Probucol, (88) 69; (88) 175
Proliferation, (88) 227

Rabbit, (88) 87
Reverse cholesterol transport, (88) 99
Rice bran oil, (88) 133
mRNA, (88) 15

Saturated fat, (88) 133
Scavenger receptor, (88) 163
Serotonin, (88) 29; (88) 213
Serum cholesterol, (88) 61
Signal transduction, (88) 109
Smooth muscle cells, (88) 213; (88) 227
Squalene, (88) 183
Squalene epoxidase inhibitor, (88) 183
Streptozotocin diabetes, (88) 69

TGF-β, (88) 227
Tryptophan, (88) 1
Type III hyperlipidemia, (88) 15

VLDL turnover, (88) 69